% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jost:1023535,
      author       = {Jost, Stefanie T. and Aloui, Salima and Evans, Julian and
                      Ashkan, Keyoumars and Sauerbier, Anna and Rizos, Alexandra
                      and Petry-Schmelzer, Jan Niklas and Gronostay, Alexandra and
                      Fink, Gereon R. and Visser-Vandewalle, Veerle and Antonini,
                      Angelo and Silverdale, Monty and Timmermann, Lars and
                      Martinez-Martin, Pablo and Chaudhuri, K. Ray and Dafsari,
                      Haidar S. and Martinez-Martin, Pablo and Rodriguez-Blazquez
                      , Carmen and Chaudhuri, Ray and Rizos, Alexandra and
                      Sauerbier, Anna and Parry, Miriam and Trivedi, Dhaval and
                      Martino, Davide and Odin, Per and Antonini, Angelo and
                      Stocchi, Fabrizio and van Hilten, Jacobus J and van Laar,
                      Teus and Falup-Pecurariu, Cristian and Dietrichs, Espen and
                      Lyons, Kelly E. and Weintraub, Dan and Kurtis, Monica and
                      Serrano-Dueñas, Marcos and Borges, Vanderci and Behari,
                      Madhuri and Bhattacharya, Kalyan and Kumar, Hrishikesh and
                      Singhal, Bhim and Bhidayasiri, Roongroj and Shen-Yang, Lim
                      and Gallardo, Marisol and Abe, Kazuo and Bostantjopoulou,
                      Sevasti and Martin Rabey, Jose and Micheli, Federico and
                      Rodriguez-Violante, Mayela and Riboldazzi, Giulio and
                      Catalan, Maria Jose and Ellis, Cathy and Bean, Lorna and
                      Kessel, Belinda and Worth, Paul and Shearing, Gemma and
                      Sophia, Rani and Sharma, Jagdish and Silverdale, Monty and
                      Pal, Suvankar and Ashkan, Keyoumars and Adler, Charles and
                      Barone, Paolo and Brooks, David J. and Brown, Richard and
                      Cantillon, Marc and Carroll, Camille and Coelho, Miguel and
                      Dafsari, Haidar S. and Henriksen, Tove and Hu, Michele and
                      Jenner, Peter and Kramberger, Milica and Kumar, Padma and
                      Kurtis, Mónica and Lewis, Simon and Litvan, Irene and
                      Lyons, Kelly and Masellis, Mario and Mochizuki, Hideki and
                      Morley, James F. and Nirenberg, Melissa and Pagonabarraga,
                      Javier and Panicker, Jalesh and Pavese, Nicola and Pekkonen,
                      Eero and Postuma, Ron and Rosales, Raymond and Schapira,
                      Anthony and Simuni, Tanya and Subramanian, Indu and
                      Tagliati, Michele and Timmermann, Lars and Tinazzi, Michele
                      and Toledo, Jon and Tsuboi, Yoshio and Walker, Richard},
      title        = {{N}eurostimulation for {A}dvanced {P}arkinson {D}isease and
                      {Q}uality of {L}ife at 5 {Y}ears},
      journal      = {JAMA network open},
      volume       = {7},
      number       = {1},
      issn         = {2574-3805},
      address      = {Chicago, Ill.},
      publisher    = {American Medical Association},
      reportid     = {FZJ-2024-01741},
      pages        = {e2352177 -},
      year         = {2024},
      abstract     = {Importance: Deep brain stimulation of the subthalamic
                      nucleus (STN-DBS) improves quality of life (QOL) in patients
                      with advanced Parkinson disease (PD). However, controlled
                      studies with more than 3 years of follow-up are
                      lacking.Objective: To investigate the long-term effects of
                      STN-DBS on QOL compared with standard-of-care medication
                      (MED).Design, setting, and participants: In this
                      prospective, observational, quasi-experimental, longitudinal
                      nonrandomized controlled trial, 183 patients were screened
                      for eligibility and 167 were enrolled from March 1, 2011, to
                      May 31, 2017, at 3 European university centers. Propensity
                      score matching for demographic and clinical characteristics
                      was applied to 108 patients with PD (62 in the STN-DBS group
                      and 46 in the MED group), resulting in a well-balanced,
                      matched subcohort of 25 patients per group. Data analysis
                      was performed from September 2022 to January 2023.Exposure:
                      Treatment for PD of STN-DBS or MED.Main outcomes and
                      measures: Assessments included Parkinson's Disease
                      Questionnaire 8 (PDQ-8), Unified PD Rating Scale-motor
                      examination, Scales for Outcomes in PD-activities of daily
                      living (ADL) and motor complications, and
                      levodopa-equivalent daily dose. Within-group longitudinal
                      outcome changes, between-group differences, and correlations
                      of change scores were analyzed.Results: The study population
                      in the analysis included 108 patients (mean [SD] age, 63.7
                      [8.3] years; 66 $[61.1\%]$ male). At 5-year follow-up, PDQ-8
                      and ADL worsened only in the MED group (PDQ-8 change, -10.9;
                      $95\%$ CI, -19.0 to -2.7; P = .01; ADL change: -2.0; $95\%$
                      CI, -3.1 to -0.8; P = .002), whereas both outcomes remained
                      stable in the STN-DBS group (PDQ-8 change, -4.3; $95\%$ CI,
                      -13.2 to 4.7; P = .34; ADL change, -0.8; $95\%$ CI, -2.5 to
                      1.0; P = .38). Changes in PDQ-8 and ADL correlated
                      moderately (rs = .40, P = .008). Furthermore, STN-DBS
                      outcomes were favorable for motor complications (median
                      difference in change scores between STN-DBS and MED, -2.0;
                      $95\%$ CI, -4.0 to -1.0; P = .003), mobility (-1.0; $95\%$
                      CI, -2.0 to 0; P = .03), and levodopa-equivalent daily dose
                      reduction (-821.4; $95\%$ CI, -1111.9 to -530.8; P <
                      .001).Conclusions and relevance: This study provides
                      evidence of differences in QOL outcomes at 5-year follow-up
                      between STN-DBS (stable) and MED (worsened), mainly driven
                      by the favorable effect of STN-DBS on mobility (class IIb
                      evidence). The association between changes in QOL and ADL,
                      but not motor impairment or complications, highlights the
                      relative importance of ADL outcomes for long-term DBS
                      assessments.Trial registration: German ClinicalTrials
                      Registry: DRKS00006735.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38236600},
      UT           = {WOS:001145711600006},
      doi          = {10.1001/jamanetworkopen.2023.52177},
      url          = {https://juser.fz-juelich.de/record/1023535},
}